SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001387131-20-010040
Filing Date
2020-11-16
Accepted
2020-11-16 17:23:43
Documents
13
Period of Report
2020-11-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_111620.htm   iXBRL 8-K 30481
2 PRESS RELEASE ex99-1.htm EX-99.1 12228
  Complete submission text file 0001387131-20-010040.txt   224975

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20201116.xsd EX-101.SCH 3225
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20201116_lab.xml EX-101.LAB 34591
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20201116_pre.xml EX-101.PRE 22736
6 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_111620_htm.xml XML 3595
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 201318478
SIC: 2834 Pharmaceutical Preparations